Study to Evaluate Letrozole, Pyrotinib Combined With SHR6390 in Patients With HR+/HER2+ Relapsed/Metastatic Breast Cancer
Condition: Breast Cancer Interventions: Drug: Letrozole; Drug: Pyrotinib; Drug: SHR6390 Sponsors: Fudan University; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials